Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Completed · Not applicable · Has a placebo group
Conditions studied: Substance-Related Disorders
In brief
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril).
Key facts
- Study ID
- NCT00661674
- Run by
- Stanford University
- People needed
- 10
- Starts
- 2008-04-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2017-06-05
Who can join
Age: 18 and older, up to 35. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Healthy males
- Ages 18-35
- No allergies to morphine or palonosetron
- No history of addiction or substance abuse
You may not qualify if…
- Female
- Younger than 18 or older than 35
- History of substance abuse
- Raynaud's disease or coronary artery disease
- Allergies to morphine or palonosetron
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.